Literature DB >> 11489935

Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies.

B Chackerian1, D R Lowy, J T Schiller.   

Abstract

High avidity and long-lasting autoantibodies to a self-polypeptide (TNF-alpha) were generated after parenteral vaccination of mice with low doses of virus-like particle-based (VLP-based) vaccines that were constructed by linking mouse TNF-alpha peptides to the surface of papillomavirus VLPs. High-titer autoantibodies were induced with or without coadministration of potent conventional adjuvants, but were enhanced by coadministration of CFA. Compared with immunization with the fusion protein alone, attachment to VLPs increased autoantibody titers 1,000-fold. A comparison of Ab responses against the self (TNF-alpha) and foreign components of the fusion protein showed that VLP conjugation abrogated the ability of the humoral immune system to distinguish between self and foreign. Similar levels of IgM were detected to self and foreign epitopes regardless of the assembly state of the antigen, suggesting that conjugation of self-peptides to VLPs promotes survival or expansion of mature autoreactive B cells. In a mouse model, vaccination with conjugated particles inhibited development of type II collagen-induced arthritis. Together, these results suggest a potentially flexible method to efficiently generate autoantibodies against specific self-proteins that mediate arthritis and other diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11489935      PMCID: PMC209354          DOI: 10.1172/JCI11849

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

1.  Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response.

Authors:  M Wykes; A Pombo; C Jenkins; G G MacPherson
Journal:  J Immunol       Date:  1998-08-01       Impact factor: 5.422

2.  V(D)J recombination in mature B cells: a mechanism for altering antibody responses.

Authors:  F Papavasiliou; R Casellas; H Suh; X F Qin; E Besmer; R Pelanda; D Nemazee; K Rajewsky; M C Nussenzweig
Journal:  Science       Date:  1997-10-10       Impact factor: 47.728

Review 3.  Receptor editing and commitment in B lymphocytes.

Authors:  M Hertz; D Nemazee
Journal:  Curr Opin Immunol       Date:  1998-04       Impact factor: 7.486

4.  The role of antibody concentration and avidity in antiviral protection.

Authors:  M F Bachmann; U Kalinke; A Althage; G Freer; C Burkhart; H Roost; M Aguet; H Hengartner; R M Zinkernagel
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

5.  Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles.

Authors:  B Chackerian; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

6.  Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

Authors:  D Schenk; R Barbour; W Dunn; G Gordon; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; Z Liao; I Lieberburg; R Motter; L Mutter; F Soriano; G Shopp; N Vasquez; C Vandevert; S Walker; M Wogulis; T Yednock; D Games; P Seubert
Journal:  Nature       Date:  1999-07-08       Impact factor: 49.962

Review 7.  Taming TNF: strategies to restrain this proinflammatory cytokine.

Authors:  A Eigler; B Sinha; G Hartmann; S Endres
Journal:  Immunol Today       Date:  1997-10

8.  Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist.

Authors:  L Ciapponi; D Maione; A Scoumanne; P Costa; M B Hansen; M Svenson; K Bendtzen; T Alonzi; G Paonessa; R Cortese; G Ciliberto; R Savino
Journal:  Nat Biotechnol       Date:  1997-10       Impact factor: 54.908

9.  Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 A resolution.

Authors:  F P Booy; R B Roden; H L Greenstone; J T Schiller; B L Trus
Journal:  J Mol Biol       Date:  1998-08-07       Impact factor: 5.469

10.  CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.

Authors:  R S Chu; O S Targoni; A M Krieg; P V Lehmann; C V Harding
Journal:  J Exp Med       Date:  1997-11-17       Impact factor: 14.307

View more
  79 in total

1.  Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus.

Authors:  Sang-Moo Kang; Richard W Compans
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7.

Authors:  Jerri do Carmo Caldeira; Alexander Medford; Rhonda C Kines; Christopher A Lino; John T Schiller; Bryce Chackerian; David S Peabody
Journal:  Vaccine       Date:  2010-04-29       Impact factor: 3.641

Review 3.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns.

Authors:  Martin F Bachmann; Gary T Jennings
Journal:  Nat Rev Immunol       Date:  2010-10-15       Impact factor: 53.106

4.  HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions.

Authors:  Douglas R Lowy
Journal:  J Clin Invest       Date:  2016-01-04       Impact factor: 14.808

Review 5.  Virus-based nanoparticles as platform technologies for modern vaccines.

Authors:  Karin L Lee; Richard M Twyman; Steven Fiering; Nicole F Steinmetz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-19

6.  Modulating adaptive immune responses to peptide self-assemblies.

Authors:  Jai S Rudra; Tao Sun; Katelyn C Bird; Melvin D Daniels; Joshua Z Gasiorowski; Anita S Chong; Joel H Collier
Journal:  ACS Nano       Date:  2012-01-30       Impact factor: 15.881

7.  SplitCore Technology Allows Efficient Production of Virus-Like Particles Presenting a Receptor-Contacting Epitope of Human IgE.

Authors:  A Zh Baltabekova; Zh S Shagyrova; A S Kamzina; M Voykov; Ye Zhiyenbay; E M Ramanculov; A V Shustov
Journal:  Mol Biotechnol       Date:  2015-08       Impact factor: 2.695

8.  Combinatorial approach to hepadnavirus-like particle vaccine design.

Authors:  Jean-Noel Billaud; Darrell Peterson; Margaret Barr; Antony Chen; Matti Sallberg; Fermin Garduno; Phillip Goldstein; Wendy McDowell; Janice Hughes; Joyce Jones; David Milich
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

9.  TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation.

Authors:  Hélène Le Buanec; Laure Delavallée; Natacha Bessis; Sébastien Paturance; Bernard Bizzini; Robert Gallo; Daniel Zagury; Marie-Christophe Boissier
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-08       Impact factor: 11.205

10.  Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens.

Authors:  Sang-Moo Kang; Lizheng Guo; Qizhi Yao; Ioanna Skountzou; Richard W Compans
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.